Formulation Licenses
Registered finished dosage forms (FDF), transferable tech packages and in-development in-licensing pipelines · delivered per target-market approval pathway
Licensing pipeline
JAK1 (oral)
—
- Therapy
- Immunology & Inflammation
- Status
- Candidate licensing (UB363)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
JAK1 (oral)
—
- Therapy
- Dermatology
- Status
- Candidate licensing (UB362)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
JAK1 (oral)
—
- Therapy
- Dermatology
- Status
- Candidate licensing (UB361)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
P2Y12R
—
- Therapy
- Cardiovascular
- Status
- Candidate licensing (UB360)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- United States
Licensing pipeline
UB356
—
- Therapy
- Oncology
- Status
- Candidate licensing (UB356)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
UB355
—
- Therapy
- Others > Respiratory
- Status
- Candidate licensing (UB355)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
UB354
—
- Therapy
- Infectious Diseases
- Status
- Candidate licensing (UB354)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
SYK inhibitor
—
- Therapy
- Immunology & Inflammation
- Status
- Candidate licensing (UB353)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
αActRII; αMyostatin
—
- Therapy
- Metabolic & Endocrinology
- Status
- Candidate licensing (UB352)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- South Korea
Licensing pipeline
GLP-1; GLP-2
—
- Therapy
- Metabolic & Endocrinology
- Status
- Candidate licensing (UB351)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- South Korea
Licensing pipeline
GLP-1; GLP-2
—
- Therapy
- Metabolic & Endocrinology
- Status
- Candidate licensing (UB350)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- South Korea
Licensing pipeline
ASK-1
—
- Therapy
- Gastroenterology & Hepatology
- Status
- Candidate licensing (UB349)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
Surface Antigen HBsAg
—
- Therapy
- Infectious Diseases
- Status
- Candidate licensing (UB348)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
Core Protein CpAM
—
- Therapy
- Infectious Diseases
- Status
- Candidate licensing (UB347)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
IL-6R; TNF-α
—
- Therapy
- Ophthalmology
- Status
- Candidate licensing (UB345)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
IL-6R; IL-23p19
—
- Therapy
- Immunology & Inflammation
- Status
- Candidate licensing (UB344)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
TL1A; IL-6R
—
- Therapy
- Immunology & Inflammation
- Status
- Candidate licensing (UB343)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
TL1A; TNF-α
—
- Therapy
- Rheumatology
- Status
- Candidate licensing (UB342)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
TL1A; IL-23p19
—
- Therapy
- Dermatology
- Status
- Candidate licensing (UB341)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
TL1A
—
- Therapy
- Gastroenterology & Hepatology
- Status
- Candidate licensing (UB340)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
IL-2R
—
- Therapy
- Immunology & Inflammation
- Status
- Candidate licensing (UB339)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
IL-1R1
—
- Therapy
- Rheumatology
- Status
- Candidate licensing (UB338)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
CD80; CD86
—
- Therapy
- Rheumatology
- Status
- Candidate licensing (UB337)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
IL-6R
—
- Therapy
- Immunology & Inflammation
- Status
- Candidate licensing (UB336)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
IL-6R
—
- Therapy
- Rheumatology
- Status
- Candidate licensing (UB335)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
(BsAb)
—
- Therapy
- Nephrology & Urology
- Status
- Candidate licensing (UB333)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- Unknown
Licensing pipeline
(BsAb)
—
- Therapy
- Immunology & Inflammation
- Status
- Candidate licensing (UB332)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
HPK-1
—
- Therapy
- Oncology
- Status
- Candidate licensing (UB324)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- Unknown
Licensing pipeline
FGFR2b; DNA Topoisomerase I
—
- Therapy
- Oncology
- Status
- Candidate licensing (UB323)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- Unknown
Licensing pipeline
MUC17; DNA Topoisomerase I
—
- Therapy
- Oncology
- Status
- Candidate licensing (UB322)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- Unknown
Licensing pipeline
CDH17; DNA Topoisomerase I
—
- Therapy
- Oncology
- Status
- Candidate licensing (UB321)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- Unknown
Licensing pipeline
ROR1; DNA Topoisomerase I
—
- Therapy
- Oncology
- Status
- Candidate licensing (UB320)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- Unknown
Licensing pipeline
ROR1; DNA Topoisomerase I
—
- Therapy
- Oncology
- Status
- Candidate licensing (UB319)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- Unknown
Licensing pipeline
ROR1; DNA Topoisomerase I
—
- Therapy
- Oncology
- Status
- Candidate licensing (UB318)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- Unknown
Licensing pipeline
GLP-1; GIP
—
- Therapy
- Metabolic & Endocrinology
- Status
- Candidate licensing (UB317)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- Unknown
Licensing pipeline
GLP-1; GIP
—
- Therapy
- Metabolic & Endocrinology
- Status
- Candidate licensing (UB316)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- Unknown
Licensing pipeline
GLP-1; GIP
—
- Therapy
- Metabolic & Endocrinology
- Status
- Candidate licensing (UB315)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
GLP-1 (oral)
—
- Therapy
- Metabolic & Endocrinology
- Status
- Candidate licensing (UB313)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
GLP-1 (oral)
—
- Therapy
- Metabolic & Endocrinology
- Status
- Candidate licensing (UB312)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
JAK1; JAK2
—
- Therapy
- Immunology & Inflammation
- Status
- Candidate licensing (UB310)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
JAK1; JAK2
—
- Therapy
- Dermatology
- Status
- Candidate licensing (UB309)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
VEGF-A
—
- Therapy
- Ophthalmology
- Status
- Candidate licensing (UB302)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
Insulin receptor
—
- Therapy
- Metabolic & Endocrinology
- Status
- Candidate licensing (UB298)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- Unknown
Licensing pipeline
Tumor neuantigens
—
- Therapy
- Oncology
- Status
- Candidate licensing (UB285)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
AChE
—
- Therapy
- Neurology
- Status
- Candidate licensing (UB284)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
CD38
—
- Therapy
- Oncology
- Status
- Candidate licensing (UB267)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
CD38
—
- Therapy
- Oncology
- Status
- Candidate licensing (UB266)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China
Licensing pipeline
GLP-1 R
—
- Therapy
- Metabolic & Endocrinology
- Status
- Candidate licensing (UB263)· Preclinical
- Registration
- Licensing / co-development (by target & stage)
- Markets
- China